---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-25-000094"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:29:41.330417+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Praxis reports RADIANT study positive: 56.3% median seizure reduction; Q2 net loss $71.1M

## Summary
- Vormatrigine in focal onset seizures (n=37): 56.3% median reduction in seizure frequency over 8 weeks; 22% achieved 100% reduction in last 28 days.
- Cash and investments $446.6M at June 30, 2025, providing runway into 2028.
- Q2 2025 net loss $71.1M vs $32.7M in Q2 2024; R&D expenses rose to $63.0M from $27.3M.
- Relutrigine received FDA Breakthrough Therapy Designation for SCN2A and SCN8A DEEs in July 2025.
- Initiated registrational studies: EMERALD (broad DEEs with relutrigine) and EMBRAVE3 (SCN2A GoF with elsunersen).

## SEC filing metadata
- accession: 0001689548-25-000094
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/0001689548-25-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/prax-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-25-000094
- JSON: https://secwatch.observer/filing/0001689548-25-000094.json
- Plain text: https://secwatch.observer/filing/0001689548-25-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.